Role of the Cyclic AMP-Protein Kinase A Pathway in Lipopolysaccharide-induced Nitric Oxide Synthase Expression in RAW 264.7 Macrophages

Ching‐Chow Chen, Kuo-Tung Chiu, Yi-Tau Sun, Wei‐Chyuan Chen

Journal of Biological Chemistry · 1999 · 111 citations · 26 references

DOIFull text

Open access

Concepts

Abstract

The signaling pathway for lipopolysaccharide (LPS)-induced nitric oxide (NO) release in RAW 264.7 macrophages involves the protein kinase C and p38 activation pathways (Chen, C. C., Wang, J. K., and Lin, S. B. (1998) J. Immunol. 161, 6206–6214; Chen, C. C., and Wang, J. K. (1999) Mol. Pharmacol. 55, 481–488). In this study, the role of the cAMP-dependent protein kinase A (PKA) pathway was investigated. The PKA inhibitors, KT-5720 and H8, reduced LPS-induced NO release and inducible nitric oxide synthase (iNOS) expression. The direct PKA activator, Bt2cAMP, caused concentration-dependent NO release and iNOS expression, as confirmed by immunofluorescence studies. The intracellular cAMP concentration did not increase until after 6 h of LPS treatment. Two cAMP-elevating agents, forskolin and cholera toxin, potentiated the LPS-induced NO release and iNOS expression. Stimulation of cells with LPS or Bt2cAMP for periods of 10 min to 24 h caused nuclear factor-κB (NF-κB) activation in the nuclei, as shown by detection of NF-κB-specific DNA-protein binding. The PKA inhibitor, H8, inhibited the NF-κB activation induced by 6- or 12-h treatment with LPS but not that induced after 1, 3, or 24 h. The cyclooxygenase-2 (COX-2) inhibitors, NS-398 and indomethacin, attenuated LPS-induced NO release, iNOS expression, and NF-κB DNA-protein complex formation. LPS induced COX-2 expression in a time-dependent manner, and prostaglandin E2production was induced in parallel. These results suggest that 6 h of treatment with LPS increases intracellular cAMP levels via COX-2 induction and prostaglandin E2 production, resulting in PKA activation, NF-κB activation, iNOS expression, and NO production. The signaling pathway for lipopolysaccharide (LPS)-induced nitric oxide (NO) release in RAW 264.7 macrophages involves the protein kinase C and p38 activation pathways (Chen, C. C., Wang, J. K., and Lin, S. B. (1998) J. Immunol. 161, 6206–6214; Chen, C. C., and Wang, J. K. (1999) Mol. Pharmacol. 55, 481–488). In this study, the role of the cAMP-dependent protein kinase A (PKA) pathway was investigated. The PKA inhibitors, KT-5720 and H8, reduced LPS-induced NO release and inducible nitric oxide synthase (iNOS) expression. The direct PKA activator, Bt2cAMP, caused concentration-dependent NO release and iNOS expression, as confirmed by immunofluorescence studies. The intracellular cAMP concentration did not increase until after 6 h of LPS treatment. Two cAMP-elevating agents, forskolin and cholera toxin, potentiated the LPS-induced NO release and iNOS expression. Stimulation of cells with LPS or Bt2cAMP for periods of 10 min to 24 h caused nuclear factor-κB (NF-κB) activation in the nuclei, as shown by detection of NF-κB-specific DNA-protein binding. The PKA inhibitor, H8, inhibited the NF-κB activation induced by 6- or 12-h treatment with LPS but not that induced after 1, 3, or 24 h. The cyclooxygenase-2 (COX-2) inhibitors, NS-398 and indomethacin, attenuated LPS-induced NO release, iNOS expression, and NF-κB DNA-protein complex formation. LPS induced COX-2 expression in a time-dependent manner, and prostaglandin E2production was induced in parallel. These results suggest that 6 h of treatment with LPS increases intracellular cAMP levels via COX-2 induction and prostaglandin E2 production, resulting in PKA activation, NF-κB activation, iNOS expression, and NO production. nitric oxide inducible nitric oxide synthase lipopolysaccharide protein kinase C dibutyryl cyclic AMP protein kinase A nuclear factor κB cyclooxygenase prostaglandin electrophoretic mobility shift assay cholera toxin Tris-buffered saline/Tween 20 Nitric oxide (NO)1 has been identified as an important signaling molecule involved in regulating a wide range of biological activities in the neural, vascular, and immune systems (1Moncada S. Palmer R.M. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar). NO and its metabolites mediate a number of host defense functions mediated by activated macrophages, including antimicrobial and tumoricidal activity, implicated in the pathogenesis of tissue damage associated with acute and chronic inflammation (2MacMicking J. Xie Q.W. Nathan C. Annu. Rev. Immunol. 1997; 15: 323-350Crossref PubMed Scopus (3446) Google Scholar, 3Laskin D.L. Pendino K.J. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 655-677Crossref PubMed Scopus (577) Google Scholar). Macrophages generate NO from the guanidino moiety of l-arginine via a reaction catalyzed by the inducible form of nitric oxide synthase (iNOS) (4Leone A.M. Palmer R.M. Knowles R.G. Francis P.L. Ashton D.S. Moncada S. J. Biol. Chem. 1991; 266: 23790-23795Abstract Full Text PDF PubMed Google Scholar). iNOS has been identified in a wide variety of cell types including macrophages, mesangial cells, vascular smooth muscle cells, keratinocytes, chondrocytes, osteoclasts, and hepatocytes and can be induced by many immune stimuli (1Moncada S. Palmer R.M. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar, 5Nathan C. Xie Q.W. J. Biol. Chem. 1994; 269: 13725-13728Abstract Full Text PDF PubMed Google Scholar). Changes in NO formation in iNOS-expressing cells usually correlate with similar changes in iNOS mRNA levels, indicating that a major part of iNOS regulation occurs at the transcription level. The promoter region of the iNOS gene contains several binding sites for transcriptional factors, such as nuclear factor-κB (NF-κB) and activator protein-1, as well as for various members of the CCAAT/enhancer-binding protein, activating transcription factor/cAMP-response element-binding protein, and Stat families of transcriptional factors (6Lowenstein C.L. Alley E.W. Raval P. Snowman A.M. Synder S.H. Russell S.W. Murphy W.J. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 9730-9734Crossref PubMed Scopus (1002) Google Scholar). Of these, the proteins of the NF-κB family appear to be essential for the enhanced iNOS gene expression seen in macrophages exposed to the active component of endotoxin, lipopolysaccharide (LPS) (7Xie Q.W. Kashiwabara Y. Nathan C. J. Biol. Chem. 1994; 269: 4705-4708Abstract Full Text PDF PubMed Google Scholar). In unstimulated cells, NF-κB is retained in the cytoplasm by binding to IκB but is released by signal induction and translocates to the nucleus, activating the responsive gene (8Thanos D. Maniatis T. Cell. 1995; 80: 529-532Abstract Full Text PDF PubMed Scopus (1216) Google Scholar). In macrophages, iNOS induction by LPS requires initiation of gene expression and de novo protein synthesis over a period of several hours (9Lyons C.R. Orloff G.J. Cunningham J.M. J. Biol. Chem. 1992; 267: 6370-6374Abstract Full Text PDF PubMed Google Scholar).The intracellular signaling pathways by which LPS causes iNOS expression in macrophages involve a series of events resulting in the transmission of the signal from the plasma membrane through the cytoplasm to the nucleus, where iNOS gene expression is up-regulated. Previous studies have shown that LPS first binds to LPS-binding protein and then to membrane CD14 and that it also activates phosphatidylinositol-phospholipase C and phosphatidylcholine-PLC by tyrosine phosphorylation, thus causing PKC activation (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar). Tyrosine phosphorylation also causes p38 activation (11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google Scholar). These phosphorylation processes result in stimulation of NF-κB DNA-protein binding and the initiation of iNOS expression and NO release (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google Scholar). An increase in intracellular cAMP levels is an important intracellular signaling mechanism involved in the regulation of gene expression. Certainin vitro studies have shown that an increase in cAMP levels causes iNOS induction (12Jeon Y.J. Yang K.H. Pulaski J.T. Kaminski N.E. Mol. Pharmacol. 1996; 50: 334-341PubMed Google Scholar, 13Nusing R.M. Klein T. Pfeilschifter J. Ullrich V. Biochem. J. 1996; 313: 617-623Crossref PubMed Scopus Google Scholar, K. K. K. P. J. Pharmacol. 1994; PubMed Scopus Google in cAMP levels caused a in iNOS K. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, S.B. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). In the study, the intracellular signaling pathway for the LPS-induced increase in cAMP levels and its in NO in RAW 264.7 The results after 6 h of LPS can increase cAMP levels by induction of cyclooxygenase-2 (COX-2) and formation of prostaglandin resulting in the activation of PKA and iNOS expression, and NO production. The PKA activation pathway in this a the PKC and p38 activation pathways have (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google of cAMP iNOS expression have been of the first that cAMP-elevating induced iNOS in vascular smooth muscle cells and that this induction was with that by Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). have also been seen in mesangial cells R.M. Klein T. Pfeilschifter J. Ullrich V. Biochem. J. 1996; 313: 617-623Crossref PubMed Scopus Google Scholar, T. Ullrich V. Pfeilschifter J. Mol. Pharmacol. 1998; PubMed Scopus Google and C. 1997; PubMed Scopus Google Scholar). cAMP not iNOS in unstimulated it iNOS induction in cells J. 1996; PubMed Google Scholar). In signaling including of to the induction of iNOS by NF-κB C. V. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar). In of cAMP levels has been shown to iNOS in or or cells K. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, S.B. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Biochem. J. 1997; PubMed Scopus Google Scholar). In RAW 264.7 macrophages, is by the cAMP thus to iNOS gene expression in to LPS and of LPS-induced activation of iNOS gene expression (12Jeon Y.J. Yang K.H. Pulaski J.T. Kaminski N.E. Mol. Pharmacol. 1996; 50: 334-341PubMed Google indicating in iNOS expression in cells, LPS by cAMP In the study, the PKA inhibitors, KT-5720 and H8, inhibited LPS-induced NO release and iNOS expression in a manner, indicating that the LPS is to the activation The cAMP Bt2cAMP, also NO release and iNOS immunofluorescence also iNOS expression in the LPS caused a time-dependent increase in cAMP levels that was with treatment and then In macrophages, the increase in cAMP levels occurs after 6 h of treatment with LPS S. Y. R.M. T. T. 1995; Scopus Google and PKA is involved in the LPS-induced activation of and NF-κB Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google activation of NF-κB-specific DNA-protein complex formation was seen after to treatment with and a similar of activation of this complex was seen Bt2cAMP In with the seen PKC or p38 (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google cells for min with H8, the NF-κB-specific DNA-protein complex formation seen after h of LPS treatment was the complex formation seen after 6 h of LPS treatment was inhibited by H8, thus with the cAMP seen after 6 h of treatment in with the PKC and p38 activation which (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google the activation pathway is a in LPS-induced NF-κB cAMP NF-κB activation and iNOS transcription via cAMP-dependent phosphorylation of the cAMP element-binding protein Mol. 1992; Scopus Google Scholar). In RAW cells, the activation of NF-κB by PKC and p38 with the activation of NF-κB by the to the LPS-induced iNOS expression and NO the activation pathway is a in LPS-induced NF-κB activation, the mechanism involved in LPS-induced increase in cAMP levels was NS-398 and an LPS-induced NO release, iNOS expression, and NF-κB activation, indicating the of COX-2 expression in NO the of various periods of LPS treatment was COX-2 expression was seen in unstimulated cells or after h of but COX-2 expression was seen after h of treatment and to increase to 24 h. is a in as it the of to which is then by or to a variety of active J. 1994; PubMed Scopus Google Scholar). cyclooxygenase and to COX-2 is a that is induced in a number of cells by stimuli and is to to the of at sites of inflammation J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar, D. Cell. 1995; Full Text PDF PubMed Scopus Google it is to be for of Cell. 1995; Scholar). LPS treatment was also and the increases after 1, 3, or 24 h of treatment and of levels, the increase in COX-2 expression. via of cAMP and activation of PKA T. J. Immunol. 1995; Google Scholar). seen in a the of smooth muscle cells D. C. Y. Mol. Pharmacol. 1998; Google in the study, induction of synthesis the increase in and as an factor for LPS-induced cell in cells is also of levels of and this is inhibited by S. Chem. 1991; PubMed Scopus Google Scholar). In macrophages, LPS is to via to increase cAMP levels K. Cell. Immunol. 1993; PubMed Scopus Google in RAW 264.7 cells, LPS increases iNOS expression via a and cAMP-dependent and this is by PKA activation of The increase in of COX-2 expression. has a with the PKC and p38 activation pathways A of the signaling pathway for the LPS-induced NO release in RAW cells is shown in Nitric oxide (NO)1 has been identified as an important signaling molecule involved in regulating a wide range of biological activities in the neural, vascular, and immune systems (1Moncada S. Palmer R.M. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar). NO and its metabolites mediate a number of host defense functions mediated by activated macrophages, including antimicrobial and tumoricidal activity, implicated in the pathogenesis of tissue damage associated with acute and chronic inflammation (2MacMicking J. Xie Q.W. Nathan C. Annu. Rev. Immunol. 1997; 15: 323-350Crossref PubMed Scopus (3446) Google Scholar, 3Laskin D.L. Pendino K.J. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 655-677Crossref PubMed Scopus (577) Google Scholar). Macrophages generate NO from the guanidino moiety of l-arginine via a reaction catalyzed by the inducible form of nitric oxide synthase (iNOS) (4Leone A.M. Palmer R.M. Knowles R.G. Francis P.L. Ashton D.S. Moncada S. J. Biol. Chem. 1991; 266: 23790-23795Abstract Full Text PDF PubMed Google Scholar). iNOS has been identified in a wide variety of cell types including macrophages, mesangial cells, vascular smooth muscle cells, keratinocytes, chondrocytes, osteoclasts, and hepatocytes and can be induced by many immune stimuli (1Moncada S. Palmer R.M. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar, 5Nathan C. Xie Q.W. J. Biol. Chem. 1994; 269: 13725-13728Abstract Full Text PDF PubMed Google Scholar). Changes in NO formation in iNOS-expressing cells usually correlate with similar changes in iNOS mRNA levels, indicating that a major part of iNOS regulation occurs at the transcription level. The promoter region of the iNOS gene contains several binding sites for transcriptional factors, such as nuclear factor-κB (NF-κB) and activator protein-1, as well as for various members of the CCAAT/enhancer-binding protein, activating transcription factor/cAMP-response element-binding protein, and Stat families of transcriptional factors (6Lowenstein C.L. Alley E.W. Raval P. Snowman A.M. Synder S.H. Russell S.W. Murphy W.J. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 9730-9734Crossref PubMed Scopus (1002) Google Scholar). Of these, the proteins of the NF-κB family appear to be essential for the enhanced iNOS gene expression seen in macrophages exposed to the active component of endotoxin, lipopolysaccharide (LPS) (7Xie Q.W. Kashiwabara Y. Nathan C. J. Biol. Chem. 1994; 269: 4705-4708Abstract Full Text PDF PubMed Google Scholar). In unstimulated cells, NF-κB is retained in the cytoplasm by binding to IκB but is released by signal induction and translocates to the nucleus, activating the responsive gene (8Thanos D. Maniatis T. Cell. 1995; 80: 529-532Abstract Full Text PDF PubMed Scopus (1216) Google Scholar). In macrophages, iNOS induction by LPS requires initiation of gene expression and de novo protein synthesis over a period of several hours (9Lyons C.R. Orloff G.J. Cunningham J.M. J. Biol. Chem. 1992; 267: 6370-6374Abstract Full Text PDF PubMed Google Scholar). The intracellular signaling pathways by which LPS causes iNOS expression in macrophages involve a series of events resulting in the transmission of the signal from the plasma membrane through the cytoplasm to the nucleus, where iNOS gene expression is up-regulated. Previous studies have shown that LPS first binds to LPS-binding protein and then to membrane CD14 and that it also activates phosphatidylinositol-phospholipase C and phosphatidylcholine-PLC by tyrosine phosphorylation, thus causing PKC activation (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar). Tyrosine phosphorylation also causes p38 activation (11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google Scholar). These phosphorylation processes result in stimulation of NF-κB DNA-protein binding and the initiation of iNOS expression and NO release (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google Scholar). An increase in intracellular cAMP levels is an important intracellular signaling mechanism involved in the regulation of gene expression. Certainin vitro studies have shown that an increase in cAMP levels causes iNOS induction (12Jeon Y.J. Yang K.H. Pulaski J.T. Kaminski N.E. Mol. Pharmacol. 1996; 50: 334-341PubMed Google Scholar, 13Nusing R.M. Klein T. Pfeilschifter J. Ullrich V. Biochem. J. 1996; 313: 617-623Crossref PubMed Scopus Google Scholar, K. K. K. P. J. Pharmacol. 1994; PubMed Scopus Google in cAMP levels caused a in iNOS K. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, S.B. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). In the study, the intracellular signaling pathway for the LPS-induced increase in cAMP levels and its in NO in RAW 264.7 The results after 6 h of LPS can increase cAMP levels by induction of cyclooxygenase-2 (COX-2) and formation of prostaglandin resulting in the activation of PKA and iNOS expression, and NO production. The PKA activation pathway in this a the PKC and p38 activation pathways have (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google Scholar). of cAMP iNOS expression have been of the first that cAMP-elevating induced iNOS in vascular smooth muscle cells and that this induction was with that by Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). have also been seen in mesangial cells R.M. Klein T. Pfeilschifter J. Ullrich V. Biochem. J. 1996; 313: 617-623Crossref PubMed Scopus Google Scholar, T. Ullrich V. Pfeilschifter J. Mol. Pharmacol. 1998; PubMed Scopus Google and C. 1997; PubMed Scopus Google Scholar). cAMP not iNOS in unstimulated it iNOS induction in cells J. 1996; PubMed Google Scholar). In signaling including of to the induction of iNOS by NF-κB C. V. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar). In of cAMP levels has been shown to iNOS in or or cells K. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, S.B. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Biochem. J. 1997; PubMed Scopus Google Scholar). In RAW 264.7 macrophages, is by the cAMP thus to iNOS gene expression in to LPS and of LPS-induced activation of iNOS gene expression (12Jeon Y.J. Yang K.H. Pulaski J.T. Kaminski N.E. Mol. Pharmacol. 1996; 50: 334-341PubMed Google indicating in iNOS expression in cells, LPS by cAMP In the study, the PKA inhibitors, KT-5720 and H8, inhibited LPS-induced NO release and iNOS expression in a manner, indicating that the LPS is to the activation The cAMP Bt2cAMP, also NO release and iNOS immunofluorescence also iNOS expression in the LPS caused a time-dependent increase in cAMP levels that was with treatment and then In macrophages, the increase in cAMP levels occurs after 6 h of treatment with LPS S. Y. R.M. T. T. 1995; Scopus Google and PKA is involved in the LPS-induced activation of and NF-κB Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google activation of NF-κB-specific DNA-protein complex formation was seen after to treatment with and a similar of activation of this complex was seen Bt2cAMP In with the seen PKC or p38 (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google cells for min with H8, the NF-κB-specific DNA-protein complex formation seen after h of LPS treatment was the complex formation seen after 6 h of LPS treatment was inhibited by H8, thus with the cAMP seen after 6 h of treatment in with the PKC and p38 activation which (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google the activation pathway is a in LPS-induced NF-κB cAMP NF-κB activation and iNOS transcription via cAMP-dependent phosphorylation of the cAMP element-binding protein Mol. 1992; Scopus Google Scholar). In RAW cells, the activation of NF-κB by PKC and p38 with the activation of NF-κB by the to the LPS-induced iNOS expression and NO the activation pathway is a in LPS-induced NF-κB activation, the mechanism involved in LPS-induced increase in cAMP levels was NS-398 and an LPS-induced NO release, iNOS expression, and NF-κB activation, indicating the of COX-2 expression in NO the of various periods of LPS treatment was COX-2 expression was seen in unstimulated cells or after h of but COX-2 expression was seen after h of treatment and to increase to 24 h. is a in as it the of to which is then by or to a variety of active J. 1994; PubMed Scopus Google Scholar). cyclooxygenase and to COX-2 is a that is induced in a number of cells by stimuli and is to to the of at sites of inflammation J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar, D. Cell. 1995; Full Text PDF PubMed Scopus Google it is to be for of Cell. 1995; Scholar). LPS treatment was also and the increases after 1, 3, or 24 h of treatment and of levels, the increase in COX-2 expression. via of cAMP and activation of PKA T. J. Immunol. 1995; Google Scholar). seen in a the of smooth muscle cells D. C. Y. Mol. Pharmacol. 1998; Google in the study, induction of synthesis the increase in and as an factor for LPS-induced cell in cells is also of levels of and this is inhibited by S. Chem. 1991; PubMed Scopus Google Scholar). In macrophages, LPS is to via to increase cAMP levels K. Cell. Immunol. 1993; PubMed Scopus Google in RAW 264.7 cells, LPS increases iNOS expression via a and cAMP-dependent and this is by PKA activation of The increase in of COX-2 expression. has a with the PKC and p38 activation pathways A of the signaling pathway for the LPS-induced NO release in RAW cells is shown in The of cAMP iNOS expression have been of the first that cAMP-elevating induced iNOS in vascular smooth muscle cells and that this induction was with that by Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). have also been seen in mesangial cells R.M. Klein T. Pfeilschifter J. Ullrich V. Biochem. J. 1996; 313: 617-623Crossref PubMed Scopus Google Scholar, T. Ullrich V. Pfeilschifter J. Mol. Pharmacol. 1998; PubMed Scopus Google and C. 1997; PubMed Scopus Google Scholar). cAMP not iNOS in unstimulated it iNOS induction in cells J. 1996; PubMed Google Scholar). In signaling including of to the induction of iNOS by NF-κB C. V. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar). In of cAMP levels has been shown to iNOS in or or cells K. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, S.B. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Biochem. J. 1997; PubMed Scopus Google Scholar). In RAW 264.7 macrophages, is by the cAMP thus to iNOS gene expression in to LPS and of LPS-induced activation of iNOS gene expression (12Jeon Y.J. Yang K.H. Pulaski J.T. Kaminski N.E. Mol. Pharmacol. 1996; 50: 334-341PubMed Google indicating in iNOS expression in cells, LPS by cAMP In the study, the PKA inhibitors, KT-5720 and H8, inhibited LPS-induced NO release and iNOS expression in a manner, indicating that the LPS is to the activation The cAMP Bt2cAMP, also NO release and iNOS immunofluorescence also iNOS expression in the LPS caused a time-dependent increase in cAMP levels that was with treatment and then In macrophages, the increase in cAMP levels occurs after 6 h of treatment with LPS S. Y. R.M. T. T. 1995; Scopus Google and PKA is involved in the LPS-induced activation of and NF-κB Y. T. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google activation of NF-κB-specific DNA-protein complex formation was seen after to treatment with and a similar of activation of this complex was seen Bt2cAMP In with the seen PKC or p38 (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google cells for min with H8, the NF-κB-specific DNA-protein complex formation seen after h of LPS treatment was the complex formation seen after 6 h of LPS treatment was inhibited by H8, thus with the cAMP seen after 6 h of treatment in with the PKC and p38 activation which (10Chen C.C. Wang J.K. Lin S.B. J. Immunol. 1998; 161: 6206-6214PubMed Google Scholar, 11Chen C.C. Wang J.K. Mol. Pharmacol. 1999; 55: 481-488Crossref PubMed Scopus (89) Google the activation pathway is a in LPS-induced NF-κB cAMP NF-κB activation and iNOS transcription via cAMP-dependent phosphorylation of the cAMP element-binding protein Mol. 1992; Scopus Google Scholar). In RAW cells, the activation of NF-κB by PKC and p38 with the activation of NF-κB by the to the LPS-induced iNOS expression and NO the activation pathway is a in LPS-induced NF-κB activation, the mechanism involved in LPS-induced increase in cAMP levels was NS-398 and an LPS-induced NO release, iNOS expression, and NF-κB activation, indicating the of COX-2 expression in NO the of various periods of LPS treatment was COX-2 expression was seen in unstimulated cells or after h of but COX-2 expression was seen after h of treatment and to increase to 24 h. is a in as it the of to which is then by or to a variety of active J. 1994; PubMed Scopus Google Scholar). cyclooxygenase and to COX-2 is a that is induced in a number of cells by stimuli and is to to the of at sites of inflammation J. Biol. Chem. 1994; 269: Full Text PDF PubMed Google Scholar, D. Cell. 1995; Full Text PDF PubMed Scopus Google it is to be for of Cell. 1995; Scholar). LPS treatment was also and the increases after 1, 3, or 24 h of treatment and of levels, the increase in COX-2 expression. via of cAMP and activation of PKA T. J. Immunol. 1995; Google Scholar). seen in a the of smooth muscle cells D. C. Y. Mol. Pharmacol. 1998; Google in the study, induction of synthesis the increase in and as an factor for LPS-induced cell in cells is also of levels of and this is inhibited by S. Chem. 1991; PubMed Scopus Google Scholar). In macrophages, LPS is to via to increase cAMP levels K. Cell. Immunol. 1993; PubMed Scopus Google Scholar). In in RAW 264.7 cells, LPS increases iNOS expression via a and cAMP-dependent and this is by PKA activation of The increase in of COX-2 expression. has a with the PKC and p38 activation pathways A of the signaling pathway for the LPS-induced NO release in RAW cells is shown in

References

26